Optimal respiratory-gated [$^{18}$F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patients with pancreatic ductal adenocarcinoma

Esther M. M. Smeets 1, Dominique S. Withaar 2, Willem Grootjans 4, John J. Hermans 1, Kees van Laarhoven 3, Lioe-Fee de Geus-Oei 4,5, Martin Gotthardt 1 and Erik H. J. G. Aarnzen 1*"
**Introduction**

Pancreatic malignancies have a dismal prognosis. The primary treatment for patients with a resectable tumor is surgery, resulting in a 23% 5-year survival. In patients with unresectable tumor or metastatic disease, 5-year survival decreases to 6% [1]. Although FOLFIRINOX [2] and nab-paclitaxel [3] have shown slightly better outcome as compared to gemcitabine-containing regimen, no effective systemic treatment options are available for irresectable or distant metastatic disease [4].

2′-deoxy-2′-[18F]fluoroglucose ([18F]FDG) PET/CT scanning is not standard in the diagnostic work-up for pancreatic cancer. In most institutes, this modality is mainly used to rule out distant metastases prior to planned surgery. Recent literature suggests that metabolic features of the primary tumor might associate with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). For many other malignancies, e.g., endometrial cancer [5], non-small cell lung carcinoma [6, 7], sarcomas [8] and bone metastatic breast cancer [9], higher [18F]FDG uptake in the primary tumor tends to associate with worse OS. For PDAC, recent studies use a manifold of different metabolic parameters to correlate to OS, yielding conflicting results.

Some studies showed a significant association between standardized uptake value (SUV), mostly SUV max, and OS [10, 11], but results are equivocal [12, 13]. Measures for intratumoral heterogeneity may provide alternative biomarkers with prognostic impact [14, 15].

Several factors should be considered when metabolic parameters are assessed in PDAC. First, respiratory motion-related artifacts complicate the quantification of metabolic parameters. It is known that the movement of the diaphragm during image acquisition (with relatively long acquisition times, typically 3–4 min per bed position) causes motion artifacts, which results in blurring of anatomical borders, overestimation of lesion volume, and underestimation of radiotracer uptake in PET/CT-imaging [16–18]. Several methods of respiratory-gated imaging have been studied, including amplitude-based optimal respiratory gating (ORG) with HD Chest [18], resulting in significant decrease in lesion volume and increase in SUV mean values when compared to non-gated imaging. Results changed more drastically for lesions closer to the diaphragm. So, evaluation of metabolic behavior of pancreatic lesions could gain accuracy using ORG.

Secondly, recent literature suggests that specific genetic mutations affect tumor metabolism [19]. For example, in colorectal cancer, KRAS-mutated tumors show increased SUV max values as compared to KRAS wild-type tumors [20]. In prostate cancer, AKT1 activation was associated with accumulation of aerobic glycolysis metabolites, whereas MYC overexpression was associated with dysregulated lipid metabolism [21]. In parallel, PDAC tumors have a heterogeneous genetic mutation profile that might affect their metabolic phenotype [22–24]. Since intra-tumoral heterogeneity, as visualized and assessed on imaging studies, can play an important role in defining tumor biology [25], SUV max or SUV mean might, intrinsically to their physical definitions, not always be the most relevant parameter.

In this study, we analyzed a large cohort of patients with proven PDAC scanned with [18F]FDG PET/CT during diagnostic work-up. To investigate the impact of respiratory motion correction on the quantification of metabolic parameters, we analyzed ORG-gated [18F]FDG PET/CT and the corresponding standard [18F]FDG PET/CT for commonly used metabolic parameters, first and second-order texture features, and their correlation with OS.

**Materials and methods**

**Study design and population**

In this retrospective explorative study, data from all patients who underwent an [18F]FDG PET/CT scan at the Radboudumc in Nijmegen for suspected pancreatic malignancy between November 2004 and January 2015 were collected (Table 1). We also included patients who were scanned elsewhere and were referred for further diagnostic evaluation. The available histopathological data acquired by either biopsy or surgery were analyzed and 158 patients with histologically proven pancreatic ductal adenocarcinoma were identified (Additional file 1: Figure S1, CONSORT flowchart). In sixty-nine of these

| Characteristic                | Number/value |
|------------------------------|--------------|
| Sex                          |              |
| Male                         | 42           |
| Female                       | 27           |
| Age at PET/CT scan           |              |
| Mean (± SD)                  | 65.17 ± 8.71 |
| Median (range)               | 66 (40–82)   |
| Survival after PET/CT scan   |              |
| Mean (± SD)                  | 64.75 ± 63.36 |
| Median (range)               | 40 (1–253)   |
| Injected dose of 18F-FDG (MBq/kg) |             |
| Mean (± SD)                  | 232.99 ± 54.40 |
| Median (range)               | 231 (81–384) |
| Localization tumor           |              |
| Head                         | 50           |
| Body                         | 15           |
| Tail                         | 4            |
patients, an ORG reconstructed scan was available. We used this group to test the additional value of ORG scanning on the quantification of metabolic parameters. Both non-ORG (according to EANM guidelines) and ORG scans were correlated to OS. Given the retrospective nature of this study and the anonymized handling of data, informed consent was waived by the institutional review board (protocol CMO2018-4420). Scans were anonymized before review and the readers were unaware of the clinical or histopathological data.

**Image acquisition**

All patients fasted for a minimum of 6 h prior to intravenous administration of $^{18}$F-FDG. Subsequently, patients rested for approximately 60 min before imaging.

Whole-body PET images were acquired using a Biograph 40 mCT (Siemens Medical Solutions, Knoxville Tennessee, USA) PET/CT scanner equipped with a dual-slice CT. PET images were reconstructed according to the EANM procedure guidelines for tumor PET imaging [26]. A TrueX algorithm was used with point spread function (PSF) and time of flight (TOF) measurements, using three iterations, 21 subsets, matrix size $200 \times 200$ (pixel spacing of 4.07 mm), full width half maximum (FWHM) of 3 mm, and using 2 min of PET data. Post-processing was performed using a 3D Gaussian filter kernel, 3.0 mm. For respiratory gating, we used an amplitude-based ORG algorithm, which is integrated in the Syngo 2012A MI.PET/CT software by Siemens, designated HD Chest. The procedures were performed as previously described [18]. In short, the main user input for the ORG algorithm is the percentage duty cycle, which is the percentage of the total acquired true coincidences used for image reconstruction. The ORG algorithm calculates an optimal amplitude range for a given duty cycle, by calculating the amplitude range for different values of the lower limit ($L$). With each value of $L$, the upper limit ($U$) is adjusted to include the specified percentage of the acquired PET data, and an amplitude range ($W$) is calculated through a simple subtraction ($U - L$). The optimal amplitude range is defined as the smallest amplitude range obtained and calculated by minimizing $W$.

The reconstruction settings were kept constant between ORG and non-ORG images; the percentage of duty cycles (total acquired true coincidences used for image reconstruction) was set at 35%, corresponding with 2 min of PET data.

Low-dose CT scans for attenuation corrections were reconstructed using a B19f convolution kernel, slice thickness 5.0 mm, and CT images for anatomical reference were reconstructed using a B31f convolution kernel, slice thickness 3.0 mm.

**Image analysis**

All $^{18}$F-FDG PET/CT scans were evaluated using the Inveon Research Workspace 4.2 (Preclinical Solutions, Siemens Medical Solutions USA, Knoxville Tennessee, USA). After manual annotation of tumor region, a 40% $\text{SUV}_{\text{max}}$ isocontour was used to delineate the metabolic tumor volume. Uptake of $^{18}$F-FDG projecting over adjacent structures, for example, uptake in the duodenum or biliary stent, was manually excluded from the VOIs, unless this was identified as tumor on contrast-enhanced CT (ceCT) or magnetic resonance cholangiopancreatography (MRCP). The first and second-order features were extracted using the PyRadiomics toolbox [27]. For the texture feature extraction, the images were discretized using a fixed number of 255 bins. The texture features were extracted from the co-occurrence (GLCM), gray-level run-length (GLRLM), and gray-level size-zone texture matrices (GLSZM). These matrices were generated by considering 26 connected voxels, 13 directions in three dimensions with a distance of 1 voxel, as described previously [27].

**Statistical analysis**

Statistical analysis was performed using R Software. Quantification of metabolic parameters measured on non-ORG versus ORG scans was compared using the Wilcoxon paired $t$ test (no Gaussian distribution assumed).

Optimal cutoff values were determined for each individual parameter on both ORG and non-ORG scans, based on Cox proportional hazard model and log-rank testing in Kaplan Meier survival curves. Overall survival of a patient was defined from the date of the PET/CT acquisition until the date of the patient’s death.

Univariate analysis of the data was performed on all 69 non-ORG and ORG scans using the Cox proportional hazard model, after scaling the features using the standard-scaler of Scikit-learn [28]. Additionally, all respiratory-gated scans were compared to their corresponding non-ORG counterpart to test the additional value of respiratory-gating on quantification of metabolic parameters.

**Results**

**ORG improves the detection of pancreatic lesions and assessment of intra-tumoral heterogeneity**

Pancreatic lesions can present in a wide range of variations on $^{18}$F-FDG PET/CT, but commonly, ductal adenocarcinomas are FDG avid beyond the level of liver uptake, with corresponding hypodense lesions on ceCT. Smaller lesions can be overlooked as physiological $^{18}$F-FDG accumulation in the duodenum. Small size and low absolute level of $^{18}$F-FDG accumulation...
renders small lesions particularly prone to partial-volume effects and motion artifacts. Correction for respiratory motion artifacts improved the visual detection of small pancreatic ductal adenocarcinomas in the pancreatic head and ampullary carcinomas (Fig. 1).

Using ORG reconstruction, the visual assessment of intra-tumoral regional differences in [18F]FDG accumulation changed, revealing regions of absent [18F]FDG accumulation or multiple foci of increased [18F]FDG accumulation (Fig. 2).

---

Fig. 1 Optimal respiratory gating improves detection of small pancreatic and ampullary lesions. A [18F]FDG PET/CT scan reconstructed according to EANM guidelines (a, c) and with optimal respiratory gating (b, d), demonstrating markedly improvement of a small ampullary lesion in a 45-year old male who presented with jaundice. Endoscopic retrograde cholangiopancreatography (ERCP) showed a polyp-like lesion located at the ampulla of Vater, which was histologically characterized as metaplastic mucosa.

Fig. 2 Optimal respiratory gating impacts assessment of intra-tumoral heterogeneity. A [18F]FDG PET/CT scan reconstructed according to EANM guidelines (a, c) and with optimal respiratory gating (b, d) showing changes in the heterogeneous pattern of intra-tumor [18F]FDG uptake.
ORG significantly impacts quantification of metabolic parameters

Next, we compared pairs of standard and ORG reconstructed scans to explore the impact of respiratory motion on the quantification of metabolic parameters. In concordance with previous studies using respiratory gating techniques, the parameters SUV$_{\text{max}}$, SUV$_{\text{mean}}$, and SUV$_{\text{diff}}$ showed significantly higher values on ORG scans compared to the corresponding non-ORG scans. The other metabolic parameters, e.g., MTV40%, significantly decreased (Additional file 2: Table S1, Fig. 3).

First-order features that describe intratumoral heterogeneity changed, for example, skewness, kurtosis, standard deviation, and entropy of the histogram increased significantly in the ORG reconstructed scan. Except for the features difference entropy and gray level variance, second-order features also showed a significant increase or decrease in the ORG reconstructed scans, for example, dissimilarity and joint entropy.

Prognostic impact of metabolic parameters is affected by ORG

As the quantification of metabolic parameters changed considerably using ORG, we investigated whether their correlation with OS was consequently affected. For both standard and ORG reconstructed scans, optimal cutoff values for correlation with OS were defined. Logistic regression analysis demonstrated that the correlation with OS of most metabolic parameters changed considerably, but in an inconsistent pattern (Table 2). Standard PET-derived parameters SUV$_{\text{max}}$, SUV$_{\text{mean}}$, and SUV$_{\text{diff}}$ were no longer associated with OS after ORG reconstruction (Table 2, Fig. 4), whereas parameters that describe heterogeneity (sum entropy) became significant, or borderline significant (difference entropy, joint entropy), associated with OS (Table 2, Fig. 5).

Discussion

Current literature shows equivocal results for the correlation of metabolic parameters measured by [$^{18}$F]FDG PET/CT and survival in patients with pancreatic cancer. In this study, we retrospectively analyzed a cohort of histologically proven PDAC patients to (1) study the impact of optimal respiratory gating on the quantification of the most commonly used metabolic parameters and (2) assess whether the correlation of these metabolic parameters and OS is affected.

![Fig. 3 Optimal respiratory gating impacts the quantification of [$^{18}$F]FDG PET-derived image parameters. The quantification of PET-derived parameters changes significantly after compensating for respiratory motion, as demonstrated for a SUV$_{\text{max}}$, b SUV$_{\text{mean}}$, c skewness, d Kurtosis, e difference entropy, and f joint entropy.](image_url)
In a relatively large cohort of patients, we noted that ORG results in the improved visibility of especially smaller sized pancreatic lesions, together with better visual assessment of intratumoral heterogeneity. Furthermore, we demonstrated that ORG imaging has a significant impact on quantification of all measured metabolic parameters, including the commonly used SUV\textsubscript{max} and SUV\textsubscript{mean}, and also first- and second-order texture features that describe intratumoral heterogeneity. As expected, ORG imaging more accurately allocated measured activity to the corresponding voxel and therefore resulted in smaller measured tumor volumes with a wider range of values. Importantly, the correlation of metabolic parameters with OS significantly changed using ORG; some parameters did now correlate whereas other parameters did no longer correlate with OS.

### Table 2

Optimal respiratory gating impacts the correlation of \[^{18}F\]FDG PET-derived image features with overall survival, assessed by univariate logistic regression analysis

| Image feature               | Non-ORG HR (95%CI) | p value | ORG HR (95%CI) | p value |
|-----------------------------|--------------------|---------|----------------|---------|
| MTV                         | 1.056 (0.636–1.751) | 0.834   | 1.218 (0.638–2.322) | 0.550   |
| SUV\textsubscript{min}      | 1.206 (0.964–1.510) | 0.102   | 0.976 (0.756–1.258) | 0.850   |
| SUV\textsubscript{max}      | 1.324 (1.031–1.700) | 0.026   | 1.121 (0.860–1.461) | 0.397   |
| SUV\textsubscript{mean}     | 1.328 (1.072–1.645) | 0.008   | 1.137 (0.891–1.451) | 0.303   |
| SUV\textsubscript{diff}     | 1.360 (1.011–1.830) | 0.041   | 1.155 (0.884–1.510) | 0.288   |
| Variance                    | 1.242 (0.965–1.598) | 0.080   | 1.045 (0.792–1.378) | 0.756   |
| Skewness                    | 1.088 (0.843–1.404) | 0.516   | 0.770 (0.577–1.027) | 0.076   |
| Kurtosis                    | 0.871 (0.668–1.135) | 0.306   | 0.894 (0.663–1.206) | 0.462   |
| Entropy image               | 1.232 (0.910–1.669) | 0.177   | 1.198 (0.910–1.577) | 0.196   |
| STD                         | 1.271 (0.968–1.669) | 0.083   | 1.064 (0.812–1.395) | 0.653   |
| Energy                      | 0.999 (0.769–1.298) | 0.992   | 0.812 (0.594–1.110) | 0.181   |
| Contrast                    | 1.051 (0.813–1.359) | 0.704   | 0.809 (0.612–1.069) | 0.135   |
| Dissimilarity               | 1.056 (0.812–1.374) | 0.684   | 0.845 (0.650–1.099) | 0.208   |
| Homogeneity.1               | 0.917 (0.680–1.237) | 0.571   | 1.018 (0.793–1.309) | 0.887   |
| Homogeneity.2               | 0.899 (0.652–1.241) | 0.517   | 0.982 (0.766–1.258) | 0.884   |
| Correlation                 | 0.923 (0.724–1.178) | 0.521   | 1.181 (0.899–1.552) | 0.231   |
| Difference Entropy.1        | 1.131 (0.828–1.543) | 0.439   | 1.362 (0.989–1.876) | 0.055   |
| Joint Entropy.2             | 1.093 (0.824–1.450) | 0.535   | 1.290 (0.980–1.698) | 0.068   |
| Sum Entropy.3               | 1.086 (0.819–1.439) | 0.568   | 1.340 (1.001–1.795) | 0.048   |
| Short.Run.Emphasis          | 1.097 (0.799–1.506) | 0.565   | 1.040 (0.804–1.346) | 0.764   |
| Long.Run.Emphasis           | 0.914 (0.654–1.278) | 0.599   | 0.923 (0.702–1.214) | 0.567   |
| GrayLevel.Non-Uniformity    | 0.983 (0.590–1.639) | 0.948   | 0.967 (0.503–1.860) | 0.919   |
| GrayLevel.Non-Uniformity.Normalized | 0.976 (0.746–1.278) | 0.861   | 0.766 (0.552–1.062) | 0.101   |
| Run.Length.Non-Uniformity   | 1.059 (0.650–1.727) | 0.817   | 1.244 (0.670–2.310) | 0.489   |
| Run.Length.Non-Uniformity.Normalized | 1.094 (0.800–1.496) | 0.575   | 1.033 (0.800–1.334) | 0.804   |
| Run.Percentage              | 1.091 (0.789–1.508) | 0.598   | 1.057 (0.812–1.374) | 0.681   |
| GrayLevel.Variance          | 0.971 (0.744–1.268) | 0.832   | 0.873 (0.665–1.145) | 0.325   |
| SmallAreaHighGrayLevelEmphasis | 1.034 (0.781–1.367) | 0.818   | 1.224 (0.924–1.622) | 0.158   |
| GrayLevelNonUniformityNormalied | 0.982 (0.752–1.283) | 0.895   | 0.773 (0.559–1.067) | 0.110   |
| SizeZoneNonUniformityNormalied | 1.082 (0.824–1.420) | 0.572   | 0.876 (0.670–1.145) | 0.331   |
| SizeZoneNonUniformity       | 1.098 (0.740–1.629) | 0.643   | 1.310 (0.796–2.156) | 0.286   |
| GrayLevelNonUniformity      | 1.011 (0.625–1.637) | 0.964   | 1.063 (0.585–1.932) | 0.841   |
| LargeAreaEmphasis           | 0.831 (0.447–1.543) | 0.557   | 0.726 (0.400–1.320) | 0.254   |
| Zone.Variance               | 0.733 (0.262–2.053) | 0.555   | 0.611 (0.240–1.556) | 0.198   |
| Zone.Percentage             | 1.078 (0.801–1.451) | 0.621   | 0.963 (0.747–1.241) | 0.769   |
Recent studies on metabolic parameters and their predictive value in PDAC have yielded equivocal findings [10, 12, 13, 29], and no single parameter was confirmed to predict behavior of PDAC. The uncertainties in these observations can be addressed from different angles; first, tumor metabolism is only one feature of a highly complex tumor microenvironment that involves a multitude of different functional phenotypes [30]. Other hallmarks of cancer than tumor metabolism perhaps are more critical to clinical outcome. Secondly, PDAC are generally characterized by high stromal content, which impacts pathways of tumor metabolism.

Other metabolic processes, e.g., glutaminolysis or autophagy, are also involved to different degrees [19]. This might in part be reflected by heterogeneous patterns of glucose metabolism and renders a single PET parameter less relevant in this cancer type. Our study might help to explain the contradictory results from a technical standpoint, as it illustrates the difficulties with accurate quantification of metabolic parameters in organs just below the diaphragm and subjected to respiratory motion during acquisition.

The impact of ORG on the prognostic impact of PET-derived metabolic parameters or clinical decision-
making was beyond the scope of this study and in general involves more information than the metabolic parameters investigated here. The retrospective nature of this study and the cohort size does not allow a comprehensive multivariate analysis to investigate whether ORG-gated measurements result in improved prognostic impact. Further prospective studies are needed to establish whether $[^{18}F]$FDG PET imaging has a prognostic role and which (set of) parameters are most accurate. Furthermore, it is highly interesting to investigate in further studies whether, for example, detection of metastases in liver and lymph nodes or local tumor growth is impacted by ORG. Moreover, we investigated a homogeneous cohort with histologically proven PDAC to rule out variations by different etiologies, whereas in the clinical setting, patients with (peri-)ampullary lesions or (focal) pancreatitis will also be referred for $[^{18}F]$FDG PET/CT imaging under the suspicion of pancreatic cancer.

Although correction for respiratory motion impacts the quantification of metabolic parameters derived from PET imaging, we could not demonstrate a consistent pattern in correlation with overall survival. Given the heterogeneous nature of cancer, it can be hypothesized that metabolic parameters that assess intratumoral...
Normalization, and SUV discretization [35–37]. In this study, we adhered to the 40% SUV\textsubscript{max} threshold for tumor delineation which is widely accepted and recommended by the EANM guidelines [38]. This isocontour corresponds best with the actual dimensions of the tumor in non-ORG images. As there is no gold standard as to assess the actual tumor volume, e.g., CT or MRCP, and anatomical imaging was not standardized in this cohort, our data does not allow cross-validation of this tumor delineation method for ORG scans.

A recent study in a similar cohort of patients with PDAC suggests that first-order entropy is an independent predictor for 2-year survival [14]. As texture features are increasingly being reported to correlate with gene expression profiles [39], it is tempting to speculate that ORG imaging further improves the assessment of intratumoral heterogeneity using advanced image analyses and facilitates in vivo classification of tumor behavior in relevant clinical settings [40].

**Conclusions**

The present study demonstrates that correction for respiratory motion artifacts significantly changes the quantitative measurement of metabolic parameters, including first- and second-order measures for intratumoral heterogeneity, in primary pancreatic ductal adenocarcinoma, with direct impact on their correlation with overall survival.

**Additional files**

**Additional file 1:** Figure S1. CONSORT flow chart. (PNG 137 kb)

**Additional file 2:** Table S1. Optimal respiratory gating impacts the quantification of \[^{18}F\]FDG PET-derived image features. (DOCX 23 kb)

**Abbreviations**

\[^{18}F\]FDG: \[^{18}F\]-Deoxy-2-\[^{18}F\]fluoro-D-glucose; ceCT: Contrast-enhanced computed tomography; EANM: European Association for Nuclear Medicine; EROG: Optimal respiratory gating; ORG: Optimal respiratory gating; TLG: Total lesion glycolysis; TOF: Time of flight

**Acknowledgements**

Not applicable.

**Funding**

This work was supported by a grant from the Radboud Oncologie Fonds, partner of the Dutch Cancer Society (KUN2015-8106).

**Availability of data and materials**

Not applicable.

**Authors’ contributions**

MG and EHJGA designed the study. EMMS and DSW retrieved the data. JJP, LfGoD, and Kvl interpreted and analyzed the scans. EMMS, DSW, WG, MG, and EHJGA analyzed and interpreted the data. EMMS, DSW, and EHJGA wrote the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the medical ethical review board (region Arnhem-Nijmegen) under protocol number CMO2018-4420. The medical ethical review board waived the need of informed consent because of the retrospective nature of the study and anonymized handling of data.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grootplein-Zuid 10, PO Box 9101, 6500 HB Nijmegen, The Netherlands. 2Department of Radiology, Medisch Spectrum Twente, Enschede, The Netherlands. 3Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands. 4Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. 5Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands.

Received: 24 October 2018 Accepted: 21 February 2019

Published online: 13 March 2019

**References**

1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(12):1140–1.
2. Conroy T, et al. FOLFRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.
3. Von Hoff DD, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase III trial. J Clin Oncol. 2011;29(34):4548–54.
4. Gershman JK, et al. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer. 2014;14:671.
5. Walentowicz-Sadlecka M, et al. The preoperative maximum standardized uptake value measured by 18F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients. Biomed Res Int. 2014;2014:234813.
6. Ulger S, et al. High FDG uptake predicts poorer survival in locally advanced non-small cell lung cancer patients undergoing curative radiotherapy, independently of tumor size. J Cancer Res Clin Oncol. 2014;140(3):495–502.
7. Tong AN, et al. Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer. Med Oncol. 2014;31(1):780.
8. Eary JF, et al. Sarcoma mid-therapy \[^{18}F\]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. J Bone Joint Surg Am. 2014;96(2):152–8.
9. Ullier GA, et al. Prognostic value of quantitative \[^{18}F\]fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med. 2013;2(5):725–33.
10. Sperti C, et al. \[^{18}F\]fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg. 2003;7:953–60.
11. Chen BB, et al. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2018;45(7):1205–17.

12. Epelbaum R, et al. Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT. J Nucl Med. 2013;54(1):12–8.

13. Heinrich S, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008;248(6):1014–22.

14. Hyun SH, et al. Intratumoral heterogeneity of F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2016;43(8):1461–8. https://doi.org/10.1007/s00259-016-3316-6.

15. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–54.

16. Callahan J, et al. Motion effects on SUV and lesion volume in 3D and 4D PET scanning. Australas Phys Eng Sci Med. 2011;34(4):489–95.

17. Chang G, et al. Implementation of an automated respiratory amplitude gating technique for PET/CT: clinical evaluation. J Nucl Med. 2010;51(1):16–24.

18. Grootjans W, et al. Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. Eur Radiol. 2014;24(12):3242–50.

19. Halbrook CJ, Lysiotis CA. Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell. 2017;31(1):5–19.

20. Kawada A, et al. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRCA mutations in colorectal cancer. Clin Cancer Res. 2012;18(6):1696–703.

21. Pinlo C, et al. AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res. 2014;74(24):7198–204.

22. Waddell N, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.

23. Sahin IH, Iacobuzio-Donahue CA, O’Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets. 2016;20(3):341–59.

24. Bailey P, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.

25. O’Connor JP, et al. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res. 2015;21(2):249–57.

26. Boellaard R, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200.

27. van Griethuysen JJM, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77(21):e104–7.

28. Pedregosa F, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12:2825–30.

29. Topkan E, et al. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol. 2011;11:123.

30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

31. Tixier F, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52(3):369–78.

32. Soussan M, et al. Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer. PLoS One. 2014;9(4):e94017.

33. Hatt M, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2015;56(1):38–44.

34. Grootjans W, et al. The impact of optimal respiratory gating and image noise on evaluation of intratumor heterogeneity on 18F-FDG PET imaging of lung cancer. J Nucl Med. 2016;57(1):1692–8.

35. Leijenaar RT, et al. The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis. Sci Rep. 2015;5:11075.